Among several other vaccine strategies under preclinical development, the most promising one is virus like particle based vaccine that will be moving into human studies soon.
Introduction
Hepatitis C virus (HCV) was initially recognized as the causative agent for parenterally transmitted non-A, non-B viral hepatitis (NANBH) in 1975 [1] . Around 1988, the genome of HCV was cloned as a cDNA without seeing the viral particles themselves [2] . In 2004, an in vitro HCV replication system was established to produce viral particles in the culture medium [3] . Later, more in vitro culturing systems were developed [4] . Together with animal models including chimpanzee and genetically humanized mice, those important tools greatly facilitated study of hepatitis C virus infection and related liver disease [5] . Notably, the chimpanzee model has been proven very useful in preclinical HCV vaccine development [15] .
Nowadays HCV is globally distributed and it is estimated that more than 170 Overall, HCV causes liver-related death in more than 300,000 people annually.
Therefore, a vaccine that can efficiently prevent and treat HCV infection is urgently needed. Nevertheless, there is currently no such vaccine available but a number of approaches are in successful development and some of them have reached human clinical trials [6] [7] [8] .
With a brief introduction on genomic structure and heterogeneity of the virus, this review mainly focus on progress made so far in clinical trials of HCV vaccines.
Virion, genomic structure and diversity of HCV
HCV is a small spherical enveloped virus with a diameter of about 60 nm ( Fig.1 I) .
The virus is non-cytopathic, hepatotropic and a prototype member of the Hepacivirus in the Flaviridae family. The HCV particle consists of a core of genomic RNA surrounded by an icosahedral protective shell of nucleocapsid protein, and further encased in a lipid envelope which originates from the infected host cells. Two viral envelope glycoproteins, E1 and E2, formed heterodimers are embedded in the lipid envelope ( Fig. 1 II) .
The genome of HCV is a positive-sense single-strand RNA which is roughly 9.6 kb and contains one single open reading frame, and the 5' and 3' ends of the RNA are the untranslated regions (UTR) (Fig. 2) Based on the diversity of the genome, HCV is classified into six or seven major genotypes (with >30% overall sequence difference) and a number of different subtypes within each genotype (with 10-25% sequence difference and more than 50 sub-genotypes) [9] . [12] . It is estimated that an individual produces as many as 10 12 virions per day [13] , and the median in vivo viral mutation rate is 2.5x10 -5 mutations per nucleotide per genome replication during primary infection [14] . heterodimer adjuvanted with adjuvant MF59C (an oil-in-water emulsion) [17] .
The vaccine was given at three different dosages on day 0 and weeks 4, 24 and 48.
All subjects developed neutralizing antibodies and T-cell lymphocyte proliferation responses to E1/E2, and an inverse response to increasing amounts of antigen was noted. The vaccine was safe and generally well-tolerated at each of the three dosage levels. Neutralizing serum samples had increased affinity levels and displayed more than 2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2 [18] . Moreover, the vaccine also elicits antibodies that cross-neutralize heterologous HCV strains [19] . The HCV infected patients, respectively [20, 21] .
Following multiple injections over 6 months, the vaccine induced anti-E1 de novo E1-specific T-cell response [21] .
Moreover, intradermal administration of low dose of E1 could induce E1-specific immune responses and restimulate memory (B and T) cells in patients with resolved HCV infection [22] . Finally, studies on this vaccine progressed to a phase II placebo-controlled, multicenter trial that was published in an abstract form in 2008 [23] . The vaccine was evaluated in 122 chronically HCV infected patients who received four courses of six injections over 3 years. Humoral and cellular immune responses to the E1 protein were induced but vaccination did not prevent histological progression of liver disease [23] . Overall, the candidate therapeutic virological responses in all treatment-naïve patients [24] and an increase in sustained virological response (SVR) rates in prior non-responders patients with chronic HCV-1 infection [25] . However, more detailed data are awaited to be peer-reviewed and published. [26] . Thirty subjects received three immunizations of HCV core interferon-based therapy and only mild hepatic damage was observed [26] . Further studies are planned to evaluate this approach as a therapeutic vaccine in HCV-infected patients.
Peptide vaccines
Peptide-based vaccines induce HCV--specific T-cell immunity through the direct presentation of vaccine peptide to the T-cell receptor via HLA molecules.
Therefore, the major advantage as well as limitation of this approach is that such peptide vaccines are HLA-specific.
Consequently, their coverage will be restricted to a subset of the population. [27] . A larger phase II [28] . lower HCV-RNA relapse rates [29] .
Nevertheless, it's inconclusive regarding vaccine efficacy due to lack of an unvaccinated control group for comparison [29] . [30] . This optimized vaccine schedule (i.e. biweekly i.d. IC41
injection) was tested in 50 treatment-naïve patients with chronic HCV genotype 1 infection [31] . A significant (p=0.0013) decline of 0.21 log in HCV viral load was observed after 4 months in 44 patients and 24 weeks after the last vaccination the viral load decreased by 0.47 log (p<0.0001) in 34 subjects [31] . Intercell AG recently planned for another phase II trial that will combine IC41 with nitazoxanide (a new broad-spectrum antiviral drug) in 60 treatment-naïve patients with chronic HCV genotype 1 infection.
C35-44 peptide is a well known
HLA-A2-restricted CTL epitope derived from HCV core region. The peptide could induce CTL activity and humoral responses to both the patients and healthy donors with all the HLA class IA types in Japan [32] .
Thus, the peptide was evaluated in a phase I dose-escalation study of 26 HCV-positive patients (23 nonresponders to PEG-IFN/ribavirin and three who had refused standard therapy) [33] . Twenty-five A more than 30% decrease in alanine transaminase and alpha feto-protein was observed in 7 of 24 patients and 3 of 6 patients, respectively. The regimen was well tolerated so further evaluation with a phase II study is recommended [33] .
A 'personalized' peptide vaccine approach was adopted in another phase I clinical trial in Japan. Twelve HCV1b--positive patients who had previously failed [34] . immunotherapy in HCV patients [35] . DCs 
DNA vaccines
Substantial research efforts have been made to develop an effective hepatitis C DNA vaccine for HCV infection [36] . As the first DNA-based therapeutic vaccine candidate to reach clinical trial for HCV infection, CICGB-230 is a mixture of a plasmid (pIDKE2) expressing HCV structural antigens (core/E1/E2) with recombinant core protein (Co.120) [38] . [39] . In summary, the vaccine CICGB-230 was well tolerated and thus is a promising candidate for effective therapeutic in individuals with chronic HCV infection.
CICGB-230 was evaluated in
The second DNA-based HCV vaccine (ChronVac-C) reached a human phase I/IIa clinical trial is a plasmid expressing HCV antigens NS3/4a generated by the company Tripep AB in Stockholm, Sweden [37] . ChronVac-C was delivered severe adverse reactions were observed [37] . genes NS3-5B [16, 43] . prime-boost regimen [43] . [40] . Those patients received three weekly subcutaneous injections of 10 6 , 10 7 and 10 PEG-IFN/ribavirin treatment is planned [42] .
Viral vector vaccines
In As suggested by Roohvand F et al. [6] , a successful HCV vaccine is defined different from the conventional one. immune responses in animal models [7] . [44] . Similarly, broadly neutralizing immune responses against HCV was also achieved in genetically modified mice with vectored measles viruses expressing HCV structural proteins C-E1-E2 and a recombinant envelope protein E2 booster [45] . These findings together with the clinical trial results obtained earlier with recombinant HCV E1/E2 purified protein as a subunit vaccine [17] [18] [19] Establishment of in vitro HCV culture systems [4] has also provided the possibility of producing inactivated whole-virus vaccines that eliciting cross-neutralizing antibodies for different HCV genotypes. Those cross-neutralizing antibodies might be used for active and passive immunization strategies.
However, the use of such HCV culturing system for developing attenuated HCV viral particles as a vaccine is hindered due to potential dangers associated with it.
Other alternatives include using some currently available novel adjuvants and carriers such as Montanide, CpG ODNs and TLR9 agonists singly or in various combinations, together with different formulas of HCV antigens [7] . Such strategies may greatly facilitate future studies of HCV vaccines especially those subunit and peptide vaccines.
